Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material

An antibody-directed enzyme prodrug therapy (ADEPT) system against CEA-positive tumours is currently in phase I clinical trials. It consists of a prodrug, 4-[N,N-bis(2-iodoethyl) amino] phenoxycarbonyl L -glutamic acid (ZD2767P) and a conjugate of the F(ab')(2) anti-CEA antibody A5B7 and the ba...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Webley, S D, Francis, R J, Pedley, R B, Sharma, S K, Begent, R H J, Hartley, J A, Hochhauser, D
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group 2001
Aiheet:
Regular Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2363686/
https://ncbi.nlm.nih.gov/pubmed/11401322
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1054/bjoc.2001.1843
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia